BTNX - COVID-19 NASAL SWAB RAPID 15-MINUTE VIRAL ANTIGEN TEST KIT

PRODUCT INFORMATION

The Rapid Response^™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point of Care i.e., inpatient care setting. 

Sample: Nasal / Nasopharyngeal secretions
Format: Cassette
Quantity: 25 Tests/Kit
Time to result: 15 minutes
Storage Condition: 2-30°C/36-86°F
Test Principle: Immunochromatographic Assay

PRODUCT DESCRIPTION

The Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection, when tested twice over two (or three) days with at least 24 hours (and no more than 36 hours) between tests. This test is authorized for use at the Point of Care i.e., in patient care setting.

Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigens are generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of the disease. Laboratories are required to report all positive results to the appropriate public health authorities.

Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

The Rapid Response™ COVID-19 Antigen Rapid Test Device is intended for use by trained laboratory personnel or health care professionals.